ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
TREATMENT OF MALIGNANT GLIOMAS USING GANCICLOVIR-HYPERSENSITIVE, RIBONUCLEOTIDE REDUCTASE-DEFICIENT HERPES-SIMPLEX VIRAL MUTANT
Author(s): MINETA T, RABKIN SD, MARTUZA RL
Source: CANCER RESEARCH    Volume: 54    Issue: 15    Pages: 3963-3966    Published: AUG 1 1994  
Times Cited: 158     References: 18     
Abstract: We have demonstrated that attenuated mutants of herpes simplex virus (HSV) have therapeutic potential for malignant brain tumors. In this report, we tested a ribonucleotide reductase-deficient (RR(-)) HSV mutant as an experimental treatment for malignant brain tumors. The HSV-RR(-) mutant hrR3, containing an Escherichia coil lacZ gene insertion in the ICP6 gene that encodes the large subunit of RR, was used in this study. We examined the cytopathic effect of hrR3 (0.1 plaque-forming unit/cell) on the U-87MG human glioblastoma cell line in vitro. Only 0.2% of U-87 cells were alive 67 h postinfection. Drug sensitivity assays demonstrated that hrR3 is hypersensitive to the antiherpetic agent ganciclovir. For in vivo studies, 10 animals harboring U-87MG tumors were randomly divided and treated intraneoplastically with either 5 x 10(6) plaque-forming units of hrR3 or medium alone. The viral treatment group showed significant inhibition of tumor growth (P < 0.01; one-sided Wilcoxon rank test). Expression of the lacZ gene in hrR3, visualized by 5-bromo-4-chrolo-3-indolyl-beta- D-galactopyranoside histochemistry, could be detected in treated tumors. The therapeutic potential of this HSV-RR(-) mutant for malignant gliomas is discussed.
Document Type: Note
Language: English
Addresses:
1. GEORGETOWN UNIV, MED CTR, DEPT NEUROSURG, WASHINGTON, DC 20007 USA
2. GEORGETOWN UNIV, MED CTR, GEORGETOWN BRAIN TUMOR CTR, WASHINGTON, DC 20007 USA
Publisher: AMER ASSOC CANCER RESEARCH, PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106
Subject Category: Oncology
IDS Number: NZ246
ISSN: 0008-5472
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo